

General information about company

Name of The Company	PAR DRUGS AND CHEMICALS LIMITED
BSE Scrip Code	000000
NSE Symbol	PAR
MSE Symbol	NA
Date of Start of Financial Year	01-04-2023
Date of End of Financial Year	31-03-2024
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2023
Date of End of Reporting Period	31-03-2024
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	No

(I) We declare that the acceptance of fixed deposits by the banks/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Related party transactions

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments	Notes		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)			Interest Rate (%)	Tenure
1	Par Drugs And Chemicals Limited		Falgunbhai V Savani		Managing Director	Remuneration			Nil	25.75002	3.14167	2.65663								Textual Information(1)	
2	Par Drugs And Chemicals Limited		Falgunbhai V Savani		Managing Director	Any other transaction	Director Sitting Fees		Nil	0.3	0	0									Textual Information(2)
3	Par Drugs And Chemicals Limited		Jigneshbhai V Savani		Director & CEO	Remuneration			Nil	25.75002	3.14167	2.65663									Textual Information(3)
4	Par Drugs And Chemicals Limited		Jigneshbhai V Savani		Director & CEO	Any other transaction	Director Sitting Fees		Nil	0.3	0	0									Textual Information(4)
5	Par Drugs And Chemicals Limited		Ghanshyambhai B Savani		Whole-Time Director	Remuneration			Nil	25.75002	3.24167	3.29163									Textual Information(5)
6	Par Drugs And Chemicals Limited		Ghanshyambhai B Savani		Whole-Time Director	Any other transaction	Director Sitting Fees		Nil	0.25	0	0									Textual Information(6)
7	Par Drugs And Chemicals Limited		Sanket Bhupendrabhai Trivedi		Company Secretary	Remuneration			Nil	3.23793	0.4811	0.4811									Textual Information(7)
8	Par Drugs And Chemicals Limited		Chintan Pratapbhai Chauhan		Chief Financial Officer	Remuneration			Nil	2.99584	0.4027	0.4427									Textual Information(8)
9	Par Drugs And Chemicals Limited		Naynaben J Savani		Non-Executive Director	Any other transaction	Director Sitting Fees		Nil	0.45	0.05	0.15									Textual Information(9)
10	Par Drugs And Chemicals Limited		Kajal Chitanbhai Vaghani		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.3	0.1	0.06									Textual Information(10)
11	Par Drugs And Chemicals Limited		Krishna Mitulbhai Shah		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.8	0.1	0.315									Textual Information(11)
12	Par Drugs And Chemicals Limited		Pravin Manjibhai Bhayani		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.8	0.1	0.315									Textual Information(12)
13	Par Drugs And Chemicals Limited		Pravin Manjibhai Bhayani		Independent Director	Remuneration			Nil	12	0	1.792									Textual Information(13)

14	Par Drugs And Chemicals Limited		Bintal Bhaveshkumar Shah		Independent Director	Any other transaction	Director Sitting Fees		Nil	0.2	0.05	0.1									Textual Information(14)
15	Par Drugs And Chemicals Limited		Savani Prathambhai Ghanshyambhai		Son of Whole-Time Director	Remuneration			Nil	1.5	0.23	0.23									Textual Information(15)
Total value of transaction during the reporting period									100.38383												

Text Block

Textual Information(1)	By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India.
Textual Information(2)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(3)	By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India.
Textual Information(4)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(5)	By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved re-appointment and fixed remuneration payable, which is subsequently approved by the shareholders for a period of 5 years w.e.f. 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India.
Textual Information(6)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(7)	
Textual Information(8)	
Textual Information(9)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(10)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(11)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(12)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(13)	By considering the suggestion and approval of Nomination & Remuneration Committee and approval of Audit Committee held on 16/08/2023, the Board at its meeting held on 17/08/2023 considered and approved remuneration payable, which is subsequently approved by the shareholders for the period of one year w.e.f. 1st October, 2023 to 30th September, 2024 in the 24th Annual General Meeting held on Saturday, 16th Day of September, 2023 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India.
Textual Information(14)	By considering recommendations and approval of Audit Committee and Nomination and Remuneration Committee held on 23/08/2021, the Board at its meeting held on 24/08/2021 approved the sitting fees of Rs. 5000/- per Board and committee meeting for all director.
Textual Information(15)	Audit committee held on 27.04.2023 discussed and approved the transaction.